Kymera Therapeutics (NASDAQ:KYMR) CEO Nello Mainolfi Sells 80,000 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 80,000 shares of Kymera Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total transaction of $9,223,200.00. Following the completion of the sale, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at $76,848,624.72. The trade was a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, April 29th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $81.18, for a total value of $2,435,400.00.

Kymera Therapeutics Stock Down 0.6%

Shares of Kymera Therapeutics stock opened at $113.51 on Friday. Kymera Therapeutics, Inc. has a fifty-two week low of $36.65 and a fifty-two week high of $130.05. The business’s fifty day moving average is $86.87 and its two-hundred day moving average is $82.91. The firm has a market cap of $9.34 billion, a PE ratio of -31.80 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same quarter in the previous year, the business earned ($0.82) earnings per share. The business’s revenue for the quarter was up 55.5% on a year-over-year basis. Equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

Large investors have recently made changes to their positions in the business. Empowered Funds LLC acquired a new stake in shares of Kymera Therapeutics in the first quarter worth $203,000. Glenmede Trust Co. NA increased its holdings in Kymera Therapeutics by 3.6% in the 1st quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock valued at $565,000 after purchasing an additional 235 shares in the last quarter. Amundi purchased a new position in Kymera Therapeutics in the first quarter valued at about $249,000. California State Teachers Retirement System lifted its stake in shares of Kymera Therapeutics by 23.0% during the first quarter. California State Teachers Retirement System now owns 56,282 shares of the company’s stock worth $4,688,000 after purchasing an additional 10,540 shares in the last quarter. Finally, Eagle Health Investments LP lifted its stake in shares of Kymera Therapeutics by 7.0% during the first quarter. Eagle Health Investments LP now owns 145,816 shares of the company’s stock worth $12,145,000 after purchasing an additional 9,516 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on KYMR shares. Jefferies Financial Group initiated coverage on shares of Kymera Therapeutics in a research note on Monday, March 16th. They set a “buy” rating and a $110.00 price objective for the company. B. Riley Financial raised their target price on shares of Kymera Therapeutics from $117.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday. Loop Capital set a $97.00 target price on shares of Kymera Therapeutics in a report on Monday, June 8th. Canaccord Genuity Group upped their price target on shares of Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research report on Friday, June 26th. Finally, BTIG Research reaffirmed a “buy” rating and set a $134.00 price target on shares of Kymera Therapeutics in a research note on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $121.41.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.